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ABSTRACT 
In traditional medicine, cannabis-based preparations have been used for a thousand of years for treatment of 
various diseases. The clinical use of cannabis-based preparations is limited due to legal and ethical reasons, and 
therefore there is a lack of data for the therapeutic potential of cannabinoids. By searching the FDA site, we 
identified three approved cannabis-based medicines for treatment of anorexia, nausea and vomiting caused by 
chemotherapy and two particularly severe forms of child epilepsy (Lennox-Gastaut and Dravet's syndrome). By 
searching the EMA site, we identify only one cannabis-based medicine authorized for use in the European 
Union – Epidyolex. But, EMA recognized possible positive therapeutic outcome of three cannabinoids 
(cannabidiol, cannabinol-9-carboxylic acid (resunab and lenabasum) and cannabidivarin) for which by the 
European Commission was granted status "Orphan designation" for 12 different indications: treatment of: 
tuberous sclerosis, West syndrome, Drave's syndrome, Lennox-Gastaut's syndrome, graft-versus-host disease, 
perinatal asphyxia, glioma, systemic sclerosis, cystic fibrosis, dermatomyositis, Rett syndrome and fragile X 
syndrome. The adverse effects of cannabis preparations are primarily due to THC, which has psychotropic 
effects and used in higher doses can cause certain central nervous system (CNS) disorders. Chronic use of THC 
may cause an excessive hyperemetic syndrome, which is always weaker than the side effects that ccause 
hemotherapy. For many patients who do not respond adequate to conventional therapy, cannabis preparations 
are the only possible option evenif cannabinoids are less potent than conventional therapy. 
KEYWORDS: Approved cannabis-based medicines, Tetrahydrocannabinol (THC), Cannabidiol (CBD), 
Cannabinol (CBN), Cannabidiverin 
 
I. INTRODUCTION 
About 30 million people living in the European Union (EU) suffer from a rare disease. For the patients 
who suffer from a debilitating rare disease, finding of effective treatment is a huge challenge.The European 
Medicines Agency (EMA) plays a central role in facilitating the development and authorization of medicines 
for rare diseases [1]. 
The Committee for Orphan Medicinal Products (COMP) is the EMA committee established in 2000in 
line with Regulation (EC) No 141/2000, responsible for evaluating applications and recommending orphan 
designation of medicines for rare diseases[1]. 
Cannabinoids are the active substances derived from cannabis plant, usually cannabis flowers. 
Cannabis preparations are widespread products used to treat various painful and pathogenic conditions[2].Due 
to legal and ethical reasons, the clinical use of cannabis preparations in many countries is limited, so there is a 
lack of evidence-based medicine with which the benefit of therapy can be reiterated[3]. But the use of these 
preparations has been increasing in the last ten years. So, there is a huge evidence that cannabinoids can help in 
treatment of different pathogenic conditions, but not enough yet forfinishingthe process of marketing 
authorization.  That is the reason why COMP for these products gave opinion to grant an orphan designation for 
treatment of some life-threatening or very seriousrare diseases for which there was no alternative therapy 
available in that moment or patients have not responded adequately to it or for other reasons(adverse effects, 
allergies) patients are not able to receive approved therapy. The European Commission decides whether to grant 
an orphan designation for the medicine based on the COMP's opinion[1]. 
For the first time, a cannabis extract was approved for clinical use in Germany in 2011 for the 
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treatment of moderate to severe refractory spasticity in multiple sclerosis. Later, National Association of 
Statutory Health Insurance Physicians, and the Drug Commission of the German Medical Association issued 
the following statement: ―The benefit of treatment with cannabinoids for a number of medical indications has 
been shown in controlled trials in which predominantly standardized and/or synthetic cannabinoid preparations 
were used. The use of such preparations may therefore be reasonable for patients in whom conventional 
treatment does not achieve adequate relief of symptoms such as spasticity, pain, nausea, vomiting, or loss of 
appetite‖ [4].  
 
II. APPROVED INDICATIONS FOR CANNABIS-BASED PREPARATIONS 
The purpose of this research was to identifyall approved indications for cannabis-based preparations by 
the US Food and Drug Administration (FDA) and by the EMA.  
The systematic review was made by searching using key words:cannabinoids, THC, CBD, CBN, 
cannabidiverin, approved cannabis-based medicines and Randomized Clinical Trials (RCT).  
Standard electronic literature search published onMedline / Pubmed, Embase, The Cochrane 
Controlled Trials Register,certain websites dedicated to cannabis andofficial websites of EMA and FDA was 
used. 
 
Approved indications for cannabis-based medicines by FDA[5] 
According to the FDA, any product intended for use in the diagnosis, treatment, or prevention of a 
disease, is classified as a medicine. When approving a marketing authorization, the FDA considers the 
following essential information about the medicine:indications for what that medicine has been shown that is 
effective, information on whether the medicine has been tested in children, which side effects have been 
reported, preclinical and clinical data on the proposed use of the medicine.  
Three cannabis-based medicines are approved by FDA: 
1) Nabilone (Cesamet®) capsules 1mg, manufacturer Valeant Pharmaceuticals International. Nabilone is a 
synthetic cannabinoid, an analogue of dronabinol (tetrahydrocannabinol -THC) and it is approved by FDA for 2 
indications: treatment of chemotherapy-induced nausea and vomiting in patients who do not respond adequately 
to conventional antiemetics and as an adjunctive analgesic for neuropathic pain[6].Although its antiemetic 
action is not yet fully understood, it is apparent that there are several points in the control systems of the body at 
which nabilone could block the emetic mechanism.Numerous trials and case studies have demonstrated 
effectiveness for relieving chronic pain in multiple sclerosis[7]. 
2) Dronabinol (Marinol®) capsules of 2.5mg, 5mg and 10mg, manufacturer Solvay Pharmaceuticals. 
Dronabinol is a synthetic THC and it is approved by FDA for 2 indications:  treatment of chemotherapy-
induced nausea and vomiting in patients who do not respond to conventional antiemetics and for the treatment 
of anorexia or weight loss in people associated with syndrome ofAcquired Immune Deficiency (AIDS) [8]. 
3) EPIDYOLEX (cannabidiol - CBD) solution for oral use 100mg / ml, manufacturer GW 
Pharmaceuticals. CBD in Epidyolex is a purified liquid cannabis extract approved by the FDA in June 2018 as 
adjunctive therapy in conjunction with clobazamfor the treatment of two particularly severe forms of childhood 
epilepsy: Lennox-Gastaut and Dravet's syndromefor patients 2 years of age and older[9].The precise 
mechanisms by which cannabidiol exerts its anticonvulsant effects in humans are unknown. But it is known that 
cannabidiol does not exert its anticonvulsant effect through interaction with cannabinoid receptors. Cannabidiol 
reduces neuronal hyper-excitability through modulation of intracellular calcium via G protein-coupled receptor 
55 (GPR55) and transient receptor potential vanilloid 1 (TRPV-1) channels, as well as modulation of adenosine-
mediated signaling through inhibition of adenosine cellular uptake via the equilibrate nucleoside transporter 1 
(ENT-1) [9].  
 
Approved indications for cannabis-based medicines by EMA[1] 
By the EMA there is only one cannabis-based medicine authorized for use in the European Union – 
Epidyolex. Same as FDA, this medicine is approved as an ‗orphan medicine‘ to be used in addition to 
clobazam, to treat patients from two years of age with Lennox-Gastaut or Dravet syndrome (rare types of 
epilepsy that begin in childhood). It is also approved by EMA to be used for treatment of tuberous sclerosis.  
By searching the EMA site, we identified 3 approved cannabinoids (cannabidiol, cannabinol-9-
carboxylic acid (resunab and lenabasum) and cannabidivarin) with status "Orphan designation" for 12 different 
indications for treatment of: tuberous sclerosis, West syndrome, Drave's syndrome, Lennox-Gastaut's syndrome, 
graft-versus-host disease, perinatal asphyxia, glioma, systemic sclerosis, cystic fibrosis, dermatomyositis, Rett 
syndrome and fragile X syndrome (see Table 1). 
It is important to emphasize that the status of ―orphan designation‖ is not the same with marketing 
authorization. To qualify medicine as orphan designation, the medicine must meet a number of criteria:it must 
be intended for the treatment, prevention or diagnosis of a disease that is life-threatening or chronically 
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debilitating, the prevalence of the condition must not be more than 5 in 10,000, no satisfactory method of 
diagnosis, prevention or treatment of the condition concerned can be authorized, or, if such a method exists, the 
medicine must be of significant benefit to those affected by the condition. 
These cannabis-based preparations are expected to work by three different mechanisms: 
 Cannabidiol (CBD) act on targets that play a role in the movement of calcium in the cells, which in 
turn is important for the transmission of electrical signals in some nerve cells. Altering the movement of 
calcium is expected to reduce or prevent the seizures. Cannabidiol is also thought to act on adenosine, a 
chemical messenger in the brain that plays an important role in suppressing seizures 
 Cannabinol-9-carboxylic acid (resunab and lenabasum)attaches to receptors called cannabinoid type 2 
receptors (CB2) found on immune cells. By attaching to these receptors, it is expected to control the body's 
immune system better reducing inflammation and so improving symptoms of the condition 
 Cannabidivarin works is not clearly understood. It is thought to help reduce inflammation and damage 
to glial cells (a type of brain cell that supports and protects nerve cells), to preserve the function of mitochondria 
(the energy producing components of cells), and to have an effect on the transmission of electrical signals in 
nerve cells 
 
Active substance Used for treatment of Overview   Status “orphan 
designation” 
approved on 





Dravet syndrome  Severe myoclonic epilepsy of 
infancy (SMEI) 
15 October  2014 
EU/3/14/1339 
Perinatal asphyxia  Happens when babies are 
born without enough oxygen 
in their blood 
28 July 2015 
EU/3/15/1520 
Glioma (in combination 
with THC) 
A type of brain tumor that 
affects the 'glial' cells 




Graft vs host disease  
Complication that can affect 
patients who have had 
allogeneic hematopoietic 
(blood) stem-cell 
transplantation to treat 








Severe form of epilepsy that 
starts in childhood between 2 
and 5 years of age 
20 March 2017 
EU/3/17/1855 
West syndrome Epilepsy disorder in which 
young children have regular 
seizures (fits) called 'infantile 
spasms' 




Genetic disease that causes 
growth of benign tumors in 
different organs of the body 
(brain, lungs, heart, kidneys, 




























Cystic fibrosis  
Hereditary disease that 
affects the cells in the lungs, 
and the glands in the gut and 
pancreas, that secrete fluids 
 




(also known as 
scleroderma) 
Complex disease in which 
the immune system is 
overactive, causing 
inflammation and excessive 
production of some proteins, 
particularly collagen 
 
12 January 2017 
EU/3/16/1808 
also known as 
lenabasum 
Dermatomyositis Inflammatory disease of the 
muscles and the skin which 
26 October 2018 
EU/3/18/2070 
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causes muscle weakness and 







genetic disease characterised 
by intellectual disability as 
well as by loss of speech and 
regression of acquired skills 
between 6 and 18 months of 
age 
 
16 October 2017 
EU/3/17/1921 
Fragile X syndrome  Inherited disease 
characterized by learning 
disability 
22 February 2018 
EU/3/18/1977 
Table 1.Cannabinoids approved by EMA for treatment of rare diseases as ―orphan designation‖ medicines 
 
III. DISCUSSION 
Changes in laws in many countries to allow the legalization and use of cannabis for medical purposes 
are a sign that cannabis is becoming globally recognized and accepted among people as something that can help 
to improve their health. For these reasons, it is especially important for people to be informed about the possible 
therapeutic benefits, dosage and adverse effects associated with the use of cannabis-based preparations. 
By the FDA three cannabis-based medicines are authorized for use[5]. By the EMA there is only one 
cannabis-based medicine authorized for use in the European Union – Epidyolex. But, EMA recognized possible 
positive therapeutic outcome of three cannabinoids (cannabidiol, cannabinol-9-carboxylic acid (resunab and 
lenabasum) and cannabidivarin) for which by the European Commission was granted status "Orphan 
designation" for 12 different indications[1]. 
Data conducted in one clinical study, support the medicinal potential of Cannabinol (CBN) in anti-
cancer therapy and provides evidence that CBN inhibits proliferation and induces cell cycle arrest and apoptosis 
in glioblastoma, hepatocellular carcinoma, and breast cancer cells in a dose- and time-dependent manner [10]. 
Human clinical trials (randomized controlled trials and open-label trials) evaluating the efficacy of CBD 
as a therapeutic were identified for various medical conditions. There is clear evidence supporting the use of 
CBD for treatment of epilepsy. But, for other health conditions evidencesare with general lack of data to draw 
definitive conclusions [11-12]. Lack of efficacy of CBD for relieving pain is also reported [13-17]. 
In a situation where we have sufficient evidence for the therapeutic potential of cannabis-based 
preparations for certain indications, monitoring the adverse effects of these preparations compared with the 
adverse effects of medicines used as conventional therapy for the treatment of same conditionsis of great 
importance.  
The side effects of cannabis-based preparations are primarily due to THC, which has psychotropic 
effects, so higher doses may cause certain disorders in CNS associated with abnormal psychomotor behavior, 
drowsiness, short-term memory impairment, and intoxication[18]. Chronic use of THC can cause excessive 
hyperemic syndrome characterized by cyclic vomiting, without any other recognizable cause. However, it 
should be kept in mind that these side effects are always less severe than the side effects of chemotherapy[19]. 
Literary data confirm that the therapeutic ratio between lethal and effective dose for cannabinoidsis 
1000: 1, vs analgesics that have a therapeutic ratio of 20: 1 and antineoplastics that have a therapeutic ratio of 
1.5:1. However, due to psychotropic effects, the total daily dose of THC should generally be limited to 30 
mg/day or less, preferably in combination with CBD, to avoid psychoactive effects and the development of 
tolerance[20].  
For all risk / benefit researchers using cannabis-based preparations, a special, simple, "online" scale of 
25 questions was designed to determine the clinical benefit and side effects of cannabis use. The questions were 
divided into 5 groups, each of which has 5 questions. All questions in a particular group are either "positive" (ie 
best score is 4) or "negative" (ie best score is 0), with a total potential score between 0-100. The nature and 
design of the scale involves the use of internal logic to minimize the problems of automatic answering and 
giving contradictory answers to similar questions. A high score indicates a well-tolerated and effective product, 
while low results indicate significant side effects and / or a lack of positive clinical experience[21]. 
 
IV. CONCLUSION 
In traditional medicine, cannabis-based preparations have been used for a thousand of years for 
treatment of various diseases. By the FDA three cannabis-based medicines are authorized for use. EMA 
recognized possible positive therapeutic outcome of three cannabinoids that granted status "Orphan 
designation" for 12 different indications. 
It is important to note that for many patients who do not respond appropriately to conventional therapy, 
cannabis-based preparations have a strong advantage even in the case where cannabinoids may be less potent 
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than conventional therapy. For these patients, cannabis-based preparations are the only possible option, 
especially for the patients who suffer from a debilitating rare disease. Changes in laws in many countries to 
allow the legalization and use of cannabis for medical purposes are a sign that cannabis is becoming globally 
recognized and accepted among people as something that can help improve their health. 
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